{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:49Z","timestamp":1790717149873,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1P20GM139745"],"award-info":[{"award-number":["1P20GM139745"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1P20GM139745"],"award-info":[{"award-number":["1P20GM139745"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01NS131347"],"award-info":[{"award-number":["1R01NS131347"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["5K23NS114201"],"award-info":[{"award-number":["5K23NS114201"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01AG082693"],"award-info":[{"award-number":["1R01AG082693"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R21NS137117"],"award-info":[{"award-number":["1R21NS137117"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS117904"],"award-info":[{"award-number":["R01NS117904"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23NS105950"],"award-info":[{"award-number":["K23NS105950"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS113541"],"award-info":[{"award-number":["R01NS113541"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U54NS100064"],"award-info":[{"award-number":["U54NS100064"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["OT2OD032701"],"award-info":[{"award-number":["OT2OD032701"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-DMRDP-PTCRA"],"award-info":[{"award-number":["W81XWH-18-DMRDP-PTCRA"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12028-025-02243-y","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T20:36:37Z","timestamp":1743194197000},"page":"472-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Consequences of Disproportionate Free Valproate Elevation in Critically Ill Adult Patients: A Multicenter Retrospective Cohort Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7181","authenticated-orcid":false,"given":"Andrew J.","family":"Webb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Riker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha D.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie Z.","family":"Goodberlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Schontz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylee K.","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar F.","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"2243_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40:526\u201348.","journal-title":"Ther Drug Monit"},{"key":"2243_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/00007691-198802000-00002","volume":"10","author":"J Barre","year":"1988","unstructured":"Barre J, Didey F, Delion F, Tillement J-P. Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit. 1988;10:133.","journal-title":"Ther Drug Monit"},{"key":"2243_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2125.1978.tb01652.x","volume":"5","author":"R Gugler","year":"1978","unstructured":"Gugler R, Mueller G. Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol. 1978;5:441\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"2243_CR4","first-page":"e0746","volume":"4","author":"CS Brown","year":"2022","unstructured":"Brown CS, Liu J, Riker RR, Mara KC, Rabinstein AA, Fraser GL, et al. Evaluation of free valproate concentration in critically ill patients. Crit Care Explor. 2022;4:e0746.","journal-title":"Crit Care Explor"},{"key":"2243_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/phar.1912","volume":"37","author":"RR Riker","year":"2017","unstructured":"Riker RR, Gagnon DJ, Hatton C, May T, Seder DB, Stokem K, et al. Valproate protein binding is highly variable in ICU patients and not predicted by total serum concentrations: a case series and literature review. Pharmacotherapy. 2017;37:500\u20138.","journal-title":"Pharmacotherapy"},{"key":"2243_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2006.08.026","volume":"377","author":"A Dasgupta","year":"2007","unstructured":"Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta. 2007;377:1\u201313.","journal-title":"Clin Chim Acta"},{"key":"2243_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/JCP.0000000000000872","volume":"38","author":"G Dautzenberg","year":"2018","unstructured":"Dautzenberg G, Nederlof M, Beekman A, Egberts T, Heerdink ER. Severe cognitive impairment associated with a high free but therapeutic total concentration of valproic acid due to hypoalbuminemia in an older patient with bipolar disorder. J Clin Psychopharmacol. 2018;38:265.","journal-title":"J Clin Psychopharmacol"},{"key":"2243_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1345\/aph.19147","volume":"34","author":"JA Haroldson","year":"2000","unstructured":"Haroldson JA, Kramer LE, Wolff DL, Lake KD. Elevated free fractions of valproic acid in a heart transplant patient with hypoalbuminemia. Ann Pharmacother. 2000;34:183\u20137.","journal-title":"Ann Pharmacother"},{"key":"2243_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1176\/appi.ajp.162.4.810","volume":"162","author":"DI Mayerhoff","year":"2005","unstructured":"Mayerhoff DI, Nurenberg J, Shah S, Schleifer SJ. Neurotoxicity associated with free valproic acid. Am J Psychiatry. 2005;162:810\u2013810.","journal-title":"Am J Psychiatry"},{"key":"2243_CR10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1345\/aph.1P30a","volume":"45","author":"MM de Maat","year":"2011","unstructured":"de Maat MM, van Leeuwen HJ, Edelbroek PM. High unbound fraction of valproic acid in a hypoalbuminemic critically iii patient on renal replacement therapy. Ann Pharmacother. 2011;45:420\u2013420.","journal-title":"Ann Pharmacother"},{"key":"2243_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"2243_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707\u201310.","journal-title":"Intensive Care Med"},{"key":"2243_CR13","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"key":"2243_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"2243_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Soft. 2015;67:1\u201348.","journal-title":"J Stat Soft"},{"key":"2243_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2146\/ajhp140191","volume":"72","author":"HG Gibbs","year":"2015","unstructured":"Gibbs HG, Zimmerman DE, Shermock KM, Clarke W, Mirski MA, Lewin JJ III. Comparison of free fraction serum valproic acid concentrations between inpatients and outpatients. Am J Health-Syst Pharm. 2015;72:121\u20136.","journal-title":"Am J Health-Syst Pharm"},{"key":"2243_CR17","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1212\/WNL.0000000000011000","volume":"96","author":"U Fisch","year":"2021","unstructured":"Fisch U, Baumann SM, Semmlack S, Marsch S, R\u00fcegg S, Sutter R. Accuracy of calculated free valproate levels in adult patients with status epilepticus. Neurology. 2021;96:e102\u201310.","journal-title":"Neurology"},{"key":"2243_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/FTD.0000000000000405","volume":"39","author":"E Wallenburg","year":"2017","unstructured":"Wallenburg E, Klok B, de Jong K, de Maat M, van Erp N, Stalpers-Konijnenburg S, et al. Monitoring protein-unbound valproic acid serum concentrations in clinical practice. Ther Drug Monit. 2017;39:269.","journal-title":"Ther Drug Monit"},{"key":"2243_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12028-018-0627-4","volume":"30","author":"A Drisaldi","year":"2019","unstructured":"Drisaldi A, Weeda E, Neyens R, Orvin N, Bonilha L, Campbell Z, et al. Accuracy of valproic acid concentration correction based on serum albumin. Neurocrit Care. 2019;30:301\u20136.","journal-title":"Neurocrit Care"},{"key":"2243_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.seizure.2021.11.018","volume":"94","author":"W Nasreddine","year":"2022","unstructured":"Nasreddine W, Atweh SF, Beydoun AA, Dirani M, Nawfal O, Beydoun A. Predicting the occurrence of thrombocytopenia from free valproate levels: a prospective study. Seizure. 2022;94:33\u20138.","journal-title":"Seizure"},{"key":"2243_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00655.x","volume":"114","author":"N Segura-Bruna","year":"2006","unstructured":"Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand. 2006;114:1\u20137.","journal-title":"Acta Neurol Scand"},{"key":"2243_CR22","doi-asserted-by":"publisher","first-page":"217269","DOI":"10.1155\/2014\/217269","volume":"2014","author":"M V\u00e1zquez","year":"2014","unstructured":"V\u00e1zquez M, Fagiolino P, Maldonado C, Olmos I, Ibarra M, Alvariza S, et al. Hyperammonemia associated with valproic acid concentrations. Biomed Res Int. 2014;2014:217269.","journal-title":"Biomed Res Int"},{"key":"2243_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.9740\/mhc.2018.03.073","volume":"8","author":"E Baddour","year":"2018","unstructured":"Baddour E, Tewksbury A, Stauner N. Valproic acid\u2013induced hyperammonemia: incidence, clinical significance, and treatment management. Ment Health Clin. 2018;8:73\u20137.","journal-title":"Ment Health Clin"},{"key":"2243_CR24","doi-asserted-by":"publisher","first-page":"154042","DOI":"10.1016\/j.jcrc.2022.154042","volume":"70","author":"MT Long","year":"2022","unstructured":"Long MT, Coursin DB. Undifferentiated non-hepatic hyperammonemia in the ICU: diagnosis and management. J Crit Care. 2022;70:154042.","journal-title":"J Crit Care"},{"key":"2243_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/clpt.1980.192","volume":"28","author":"TA Bowdle","year":"1980","unstructured":"Bowdle TA, Patel IH, Levy RH, Wilensky AJ. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther. 1980;28:486\u201392.","journal-title":"Clin Pharmacol Ther"},{"key":"2243_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00606683","volume":"13","author":"U Klotz","year":"1978","unstructured":"Klotz U, Rapp T, M\u00fcller WA. Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol. 1978;13:55\u201360.","journal-title":"Eur J Clin Pharmacol"},{"key":"2243_CR27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/toxins6020416","volume":"6","author":"E Devine","year":"2014","unstructured":"Devine E, Krieter DH, R\u00fcth M, Jankovski J, Lemke H-D. Binding affinity and capacity for the uremic toxin indoxyl sulfate. Toxins. 2014;6:416\u201329.","journal-title":"Toxins"},{"key":"2243_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/ajcp\/101.3.349","volume":"101","author":"A Dasgupta","year":"1994","unstructured":"Dasgupta A, Jacques M. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds. Am J Clin Pathol. 1994;101:349\u201353.","journal-title":"Am J Clin Pathol"},{"key":"2243_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1528-1157.1979.tb04779.x","volume":"20","author":"IH Patel","year":"1979","unstructured":"Patel IH, Levy RH. Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids. Epilepsia. 1979;20:85\u201390.","journal-title":"Epilepsia"},{"key":"2243_CR30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000222789","volume":"81","author":"LA Mike","year":"2010","unstructured":"Mike LA. Propofol-related infusion syndrome. Pract Gastroenterol. 2010;81:16\u201324.","journal-title":"Pract Gastroenterol"},{"key":"2243_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1365-2125.1984.tb02414.x","volume":"17","author":"F Albani","year":"1984","unstructured":"Albani F, Riva R, Contin M, Baruzzi A, Altomare M, Merlini G, et al. Differential transplacental binding of valproic acid: influence of free fatty acids. Br J Clin Pharmacol. 1984;17:759\u201362.","journal-title":"Br J Clin Pharmacol"},{"key":"2243_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/JCP.0b013e3181b4b07c","volume":"29","author":"J de Leon","year":"2009","unstructured":"de Leon J, Kiesel JL, Fleming MW, Strobl B. Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: a case report. J Clin Psychopharmacol. 2009;29:509.","journal-title":"J Clin Psychopharmacol"},{"key":"2243_CR33","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1176\/ajp.2006.163.11.1891","volume":"163","author":"NB Sandson","year":"2006","unstructured":"Sandson NB, Marcucci C, Bourke DL, Smith-Lamacchia R. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry. 2006;163:1891\u20136.","journal-title":"Am J Psychiatry"},{"key":"2243_CR34","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1212\/WNL.37.8.1392","volume":"37","author":"KJ Goulden","year":"1987","unstructured":"Goulden KJ, Dooley JM, Camfield PR, Fraser AD. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology. 1987;37:1392\u20131392.","journal-title":"Neurology"},{"key":"2243_CR35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/j.1552-4604.1980.tb02544.x","volume":"20","author":"JS Fleitman","year":"1980","unstructured":"Fleitman JS, Bruni J, Perrin JH, Wilder BJ. Albumin-binding interactions of sodium valproate. J Clin Pharmacol. 1980;20:514\u20137.","journal-title":"J Clin Pharmacol"},{"key":"2243_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143\u201357.","journal-title":"Clin Pharmacokinet"},{"key":"2243_CR37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1528-1157.1975.tb04743.x","volume":"16","author":"P Loiseau","year":"1975","unstructured":"Loiseau P, Brachet A, Henry P. Concentration of dipropylacetate in plasma. Epilepsia. 1975;16:609\u201315.","journal-title":"Epilepsia"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-025-02243-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-025-02243-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-025-02243-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T14:24:03Z","timestamp":1757946243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-025-02243-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2243"],"URL":"https:\/\/doi.org\/10.1007\/s12028-025-02243-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.16.24307506","asserted-by":"object"}]},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A. J. Webb has received consulting fees from Grace Therapeutics Inc. D. J. Gagnon is a clinical specialist in neurosciences for Lexicomp and is supported by National Institute of General Medical Sciences grant 1P20GM139745. C. S. Brown has received consulting fees from Trevena Pharmaceuticals and grant funding from Astra Zeneca. R. R. Riker is supported by National Institutes of Health (NIH) National Institute of General Medical Sciences grant 1P20GM139745. S. F. Zafar is supported by NIH National Institute of Neurological Disorders and Stroke (NINDS) grants 1R01NS131347, 5K23NS114201, 1R01AG082693, and 1R21NS137117. E. S. Rosenthal has received consulting fees from UCB, Inc. and Ceribell, Inc. and is supported by US Department of Defense grant W81XWH-18-DMRDP-PTCRA and NIH NINDS and NIH Office of the Director grants R01NS117904, K23NS105950, R01NS113541, U54NS100064, and OT2OD032701.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The reported research adheres to ethical guidelines and was conducted under approved investigational review board protocols. This is a retrospective study with deidentified data and was exempt from informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval\/Informed Consent"}}]}}